Mechanism of Action of Miltefosine on *Leishmania donovani* Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca²⁺ Channel

Andrea K. Pinto-Martinez,[a] Jessica Rodriguez-Durán,[a] Xenon Serrano-Martin,[a] Vanessa Hernandez-Rodriguez,[a] Gustavo Benaim[a,b]

[a]Instituto de Estudios Avanzados (IDEA), Caracas, Venezuela
[b]Instituto de Biología Experimental, Facultad de Ciencias, Universidad Central de Venezuela, Caracas, Venezuela

ABSTRACT *Leishmania donovani* is the causing agent of visceral leishmaniasis, a common infection that affects millions of people from the most underdeveloped countries. Miltefosine is the only oral drug to treat infections caused by *L. donovani*. Nevertheless, its mechanism of action is not well understood. While miltefosine inhibits the synthesis of phosphatidylcholine and also affects the parasite mitochondrion, inhibiting the cytochrome *c* oxidase, it is to be expected that this potent drug also produces its effect through other targets. In this context, it has been reported that the disruption of the intracellular Ca²⁺ homeostasis represents an important object for the action of drugs in trypanosomatids. Recently, we have described a plasma membrane Ca²⁺ channel in *Leishmania mexicana*, which is similar to the L-type voltage-gated Ca²⁺ channel (VGCC) present in humans. Remarkably, the parasite Ca²⁺ channel is activated by sphingosine, while the L-type VGCC is not affected by this sphingolipid. In the present work we demonstrated that, similarly to sphingosine, miltefosine is able to activate the plasma membrane Ca²⁺ channel from *L. donovani*. Interestingly, nifedipine, the classical antagonist of the human channel, was not able to fully block the parasite plasma membrane Ca²⁺ channel, indicating that the mechanism of interaction is not identical to that of sphingosine. In this work we also show that miltefosine is able to strongly affect the acidocalcisomes from *L. donovani*, inducing the rapid alkalinization of these important organelles. In conclusion, we demonstrate two new mechanisms of action of miltefosine in *L. donovani*, both related to disruption of parasite Ca²⁺ homeostasis.

KEYWORDS *Leishmania donovani*, Ca²⁺, miltefosine, sphingosine, visceral leishmaniasis, mechanism of action

Leishmaniasis is a parasitic neglected tropical disease affecting millions of people all over the world. There are three main forms of this disease: visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous leishmaniasis, all of which are caused by 20 different *Leishmania* species, which are transmitted by phlebotomine sand flies. Current estimates indicate that from 0.2 to 0.4 million people are affected by visceral leishmaniasis, which is the most severe clinical form of the disease and usually leads the patient to death if untreated. Its etiologic agents are the trypanosomatid parasites *Leishmania infantum* (in the Americas) and *Leishmania donovani* (Asia, Middle East and Africa) (1). The classical treatments against leishmaniasis include pentavalent antimonials (glucantime and pentostan), which present serious disadvantages, such as variable efficacy, parenteral, and marked side effects. More recently, amphotericin B

administered in liposomal complex has been shown to be very efficient (2). Another class of compounds, alkyl phosphorylcholines and related derivatives, have shown efficacy against *L. donovani* (3). A similar compound derived from phosphocholine, miltefosine, was first used as an anti-neoplastic drug (4) and has shown large efficacy against *L. donovani* and other trypanosomatids like *Trypanosoma cruzi* and *Trypanosoma brucei* (5). Miltefosine also showed antiparasitic action *in vivo* on VL-infected patients in India (6). Accordingly, in the last few years miltefosine efficacy against different *Leishmania* species has been reported (7, 8). Furthermore, miltefosine has shown a synergistic effect with several drugs, among others, with nanotized curcumin against *L. donovani* (9), with amiodarone against *L. mexicana* (10), with allopurinol against canine VL produced by *L. infantum* (11), and with pentamidine against *L. infantum*-HIV coinfection (12). Despite its reported side effects as inducer of resistance and teratogenic action, evidence proving miltefosine antileishmanial action *in vitro* and *in vivo* led to its use as the first oral treatment for VL (13, 14).

In concerns to the mechanism of action of miltefosine, several compounds have been shown to act as inhibitors of lipid biosynthesis in kinetoplastid parasites. Among them, lysophospholipids produced a marked effect on the phospholipid composition of trypanosomatids, in which the biosynthesis of phosphatidylcholine (PC) is inhibited at the level of phosphatidylethanolamine N-methyltransferase (15). Miltefosine, as an alkyl-lysophospholipid, showed a reduction of the concentration of phosphatidylcholine in *T. cruzi*. Remarkably, it has been claimed that miltefosine inhibits the biosynthesis of PC in *T. cruzi* (16) with 10 to 20 times more potency compared to that of mammalian cells (17), thus explaining its high selectivity as antiparasitic drug. The same mechanism has also been reported in *L. donovani*, in which phosphatidylcholine concentration is decreased and phosphatidylethanolamine concentration is enhanced (18).

Previous reports demonstrate that miltefosine causes decreases in the oxygen consumption rate and ATP levels of *L. donovani* through inhibition of the mitochondrial cytochrome *c* oxidase (19). Furthermore, miltefosine also produces an apoptosis-like death in *L. donovani* promastigotes (20).

With regard to Ca^{2+} signaling, it is known that the mechanisms involved in Ca^{2+} regulation in trypanosomatids constitute a target for chemotherapeutic agents like amiodarone and dronedarone, which disrupt Ca^{2+} homeostasis in *T. cruzi* and *L. mexicana* (21–24) through their action on two organelles acting as Ca^{2+} compartments, the mitochondrion and the acidocalcisomes. Moreover, the antituberculosis compound SQ109, which also possesses a very potent trypanocidal effect, was recently found to act on *T. cruzi* (25) and *L. mexicana* (26) through the same mechanism of Ca^{2+} and mitochondrial disruption. Also in concerns to disruption of Ca^{2+} regulation, it has been reported that many Ca^{2+} channel antagonists produce a marked effect in several trypanosomatids (27), including *L. donovani* (28). In fact, a plasma membrane Ca^{2+} channel homolog to the human L-type voltage-gated Ca^{2+} channel (VGCC) has been described in *L. mexicana* (29). This channel shares many characteristics with its human homolog, such as antagonism by classical human channel blockers (nifedipine and verapamil). However, remarkably, the parasite channel is selectively stimulated by the sphingolipid sphingosine, while the VGCC is not (29). In the present work we show new mechanisms of action of miltefosine, demonstrating that this drug is able to activate a Ca^{2+} channel in the plasma membrane of *L. donovani* similar to the sphingosine-activated channel mentioned above for *L. mexicana*. Although miltefosine simulated the effect of sphingosine, the activation of the parasite channel by this drug was not completely blocked by dihydropyridines such as nifedipine, the classical human L-type VGCC antagonist. Furthermore, in the present work we also demonstrate that miltefosine has a direct effect on *L. donovani* acidocalcisomes.

RESULTS

Effect of miltefosine on the intracellular Ca^{2+} concentration of *L. donovani* promastigotes. Several mechanisms have been proposed for the mode of action of miltefosine on *Leishmania* spp. These include disturbances of the lipid-dependent

FIG 1 Effect of miltefosine and sphingosine on the intracellular Ca^{2+} concentration of *L. donovani* promastigotes. Promastigotes were loaded with Fura-2 and the indicated compounds were added directly to the cuvette, as described in Materials and Methods. (A) Miltefosine (4 μM) was added (arrow) in the presence of 2 mM extracellular Ca^{2+}, followed by the addition of sphingosine (10 μM). (B) Sphingosine (10 μM) was added as indicated (arrow), followed by miltefosine (4 μM). Traces are representative of at least three independent experiments.

signaling pathways (16), inhibition of cytochrome *C* oxidase (19), and an apoptosis-like cell death (30). However, there is increasing evidence that Ca^{2+} homeostasis could be a target for the action of drugs against trypanosomatids (21–24), and the role of Ca^{2+} on different cellular processes, including cell death by apoptosis and necrosis, is well known. In order to determine the effect of miltefosine on the $[Ca^{2+}]_i$ (intracellular Ca^{2+} concentration) in *L. donovani* promastigotes, the parasites were loaded with the fluorescent Ca^{2+} indicator Fura-2. It can be observed (Fig. 1) that the addition of miltefosine (4 μM) induced a large increase in the $[Ca^{2+}]_i$. We used this concentration because it has been previously shown, based on a dose-response curve, that at 4 μM miltefosine exerts its maximal effect on the magnitude of the $[Ca^{2+}]_i$ increase in *L. mexicana* (10). Addition of sphingosine (10 μM), which at this concentration is known to optimally activate the plasma membrane Ca^{2+} channel in *L. mexicana* (29), showed no further effect. Accordingly, when miltefosine was added after the rapid increase in the $[Ca^{2+}]_i$ induced by sphingosine, the drug did not produce any further increase in fluorescence. These results suggest that miltefosine and sphingosine share the same mechanism of action, namely, the opening of a Ca^{2+} channel at the plasma membrane.

We then sought to verify if the observed Ca^{2+} channel activated by miltefosine corresponds to the same entity of the sphingosine-sensitive plasma membrane Ca^{2+} channel already described in *L. mexicana* (29). For this, we used Bay K 8644, a very specific agonist of the human L-type VGCC, widely used for its functional characterization, and which has been demonstrated to indeed also activate the Ca^{2+} channel reported in *L. mexicana* (29). At 4 μM the agonist is known to induce the maximal opening of the human L-type VGCC and also the similar channel in *L. mexicana* (29). It was observed that upon addition of Bay K 8644 (Fig. 2) this agonist totally substituted the effect of miltefosine. That is, Bay K 8644 (4 μM) did not produce any further effect after addition of miltefosine (Fig. 2A) and, accordingly, addition of miltefosine after Bay K 8644 did not induce any further Ca^{2+} release (Fig. 2B). These results support the notion that both miltefosine and sphingosine act on the same channel.

We performed experiments to determine whether the effect of a dihydropyridine (nifedipine), a classical human L-type VGCC inhibitor, was able to also block the effect of miltefosine. It was observed (Fig. 3A) that nifedipine (4 μM) partially blocks the effect generated by miltefosine, while this channel blocker produces total blockade of the sphingosine action, as previously reported in *L. mexicana* (29), and shown here in Fig. 3B. In these experiments, we used nifedipine at 4 μM, since this concentration is twice

FIG 2 Effect of miltefosine and the Ca^{2+} channel agonist Bay K 8644 on the intracellular Ca^{2+} concentration of *L. donovani* promastigotes. (A) Miltefosine (4 μM) and then Bay K 8644 (4 μM) were added (arrows) directly to the cuvette in the presence of 2 mM extracellular Ca^{2+}. (B) Bay K 8644 (4 μM) was added (arrow), followed by miltefosine (4 μM) when indicated, in the presence of 2 mM extracellular Ca^{2+}. Traces are representative of at least three independent experiments. (See Materials and Methods section for details).

the amount of this antagonist known to totally block the sphingosine-activating effect on the *L. mexicana* channel (29). Addition of the mild detergent digitonin (40 μM), known to disrupt the permeability barrier of the plasma membrane without affecting intracellular organelles, induced a further increase in the Ca^{2+} signal reaching the maximal fluorescence level, as expected. Further addition of EGTA (10 mM) to chelate all extracellular Ca^{2+} caused the fluorescence signal to reach the lowest level. These results suggest that the mechanism of action of miltefosine is similar but not identical to that of sphingosine.

We then determined the effect of miltefosine in the absence of extracellular Ca^{2+}. Figure 3C shows that addition of the drug, instead of inducing an increase in the $[Ca^{2+}]_i$, reduced it to well below the basal level. This is due to the presence of EGTA, which chelates all extracellular Ca^{2+} and forces the intracellular basal Ca^{2+} to leave the cytoplasm toward the outside medium. When Ca^{2+} is restored at the extracellular milieu, a large increase was now observed, indicating that the channel had indeed been opened by miltefosine.

The effect of miltefosine after the addition of nifedipine and in the absence of extracellular Ca^{2+} was then tested (Fig. 3D). According with the results obtained in Fig. 3A and B, the release of intracellular Ca^{2+} obtained after miltefosine addition in the presence of the blocker was less than that with miltefosine alone (Fig. 3C), indicating a partial blockage of the channel and confirming that nifedipine does not completely block the activating effect exerted by miltefosine on this Ca^{2+} channel.

Effect of miltefosine on intracellular organelles of *L. donovani*. We also studied the possible effect of miltefosine on the intracellular organelles known to be involved in Ca^{2+} homeostasis, such as the acidocalcisomes and the unique giant mitochondrion present in these parasites. Concerning this last organelle, it was previously shown that miltefosine has a mitochondrial depolarizing effect, reported as an impairment of the ability of the parasites to accumulate rhodamine 123 after 14 h of treatment with miltefosine in *L. donovani* promastigotes (19). This effect was predictable since miltefosine inhibits the cytochrome *c* oxidase, which in turn would affect the mitochondrial membrane potential. We now show that miltefosine produces a very short-term collapse of the mitochondrial electrochemical membrane potential, since a fast, large increase in rhodamine 123 fluorescence was observed upon addition of miltefosine (Fig. 4A). In principle, this effect was also predictable, since miltefosine induces the entrance of Ca^{2+} and therefore its accumulation in the mitochondrion. This is known

FIG 3 Effect of the L-type VGCC channel blocker nifedipine on the action of miltefosine on the intracellular Ca^{2+} concentration of *L. donovani* promastigotes. (A) Black line indicates effects of miltefosine (4 μM) in the presence of extracellular $CaCl_2$ (2 mM), followed by digitonin (40 μM) and EGTA (arrows), respectively. Gray line indicates effects of nifedipine (4 μM), followed by miltefosine (4 μM) in the presence of 2 mM extracellular Ca^{2+}, followed by digitonin (40 μM) and EGTA (arrows), respectively. (B) Effect of nifedipine (4 μM) followed by sphingosine (10 μM), miltefosine (4 μM), digitonin (40 μM) and EGTA, respectively (arrows) in the presence of 2 mM extracellular Ca^{2+}. (C) Effect of miltefosine in the absence of extracellular Ca^{2+}. EGTA was added to chelate any contaminating extracellular Ca^{2+} (arrow), followed by miltefosine (4 μM), $CaCl_2$ (2 mM), digitonin (40 μM), and EGTA, respectively. (D) Effect of miltefosine after addition of nifedipine in the absence of extracellular Ca^{2+}. EGTA was added to chelate any contaminating extracellular Ca^{2+} (arrow), followed by nifedipine (4 μM), miltefosine (4 μM), $CaCl_2$ (2 mM), digitonin (40 μM), and EGTA, respectively. Traces are representative of at least three independent experiments.

to occur via a mitochondrial Ca^{2+} uniporter (31) also present in the *Leishmania* parasite (32), whose driving force is the mitochondrial electrochemical membrane potential. Thus, any Ca^{2+} entry would dissipate this potential, which will be translated into the release of rhodamine 123. However, the depolarizing effect of miltefosine on the parasite's mitochondrion was also observed, albeit at a lesser extent, in the absence of extracellular Ca^{2+} (Fig. 4B), indicating that this effect is partially independent of the entrance of the cation to the cell, but is a direct effect of miltefosine on this organelle. In both extracellular Ca^{2+} condition experiments we added the mitochondrial electron chain uncoupler fluorocarbonyl cyanide-*p*-(trifluoromethoxy)phenylhydrazone (FCCP) (2 μM), which is expected to completely deenergize the mitochondria at this concentration (32, 33). Only a small response was obtained for this effector after miltefosine was added in the absence of extracellular Ca^{2+} (Fig. 4B), confirming again the large

FIG 4 Effect of miltefosine on the mitochondrial electrochemical potential of *L. donovani* promastigotes. Parasites were incubated in the presence of rhodamine123 (10 mg/ml) for 30 min at room temperature, as indicated in Materials and Methods. (A) In the presence of 2 mM extracellular Ca²⁺, miltefosine (4 μM) was added (arrow), followed by FCCP (2 μM). (B) Miltefosine (4 μM) was added (arrow), followed by addition of FCCP (2 μM). This was performed in the absence of extracellular Ca²⁺. Traces are representative of at least three independent experiments.

effect of miltefosine on this organelle and its partial dependence on the entrance of extracellular Ca²⁺.

We then studied the effect of miltefosine in another very relevant compartment, associated as well with intracellular Ca²⁺ regulation and also involved in the *L. donovani* parasite's bioenergetics, the acidocalcisomes (34). We determined whether miltefosine had an effect on this organelle by the use of acridine orange, which is known to be accumulated in acidic reservoirs. These experiments were performed in the absence of extracellular Ca²⁺, to exclude the possible effect associated with the entrance of Ca²⁺ through the plasma membrane channel to the cytoplasm that could interfere with the basal Ca²⁺ content in the acidocalcisomes, and therefore with the degree of acidity. Figure 5A shows that the addition of miltefosine (4 μM) to promastigotes loaded with the fluorescent indicator produced a large increase in fluorescence due to the release of the fluorophore from the acidocalcisomes after its alkalinization


FIG 5 Effect of miltefosine on acidocalcisomes in *L. donovani* promastigotes. Parasites were loaded with acridine orange (2 mM) as described in Materials and Methods. The excitation wavelength was 488 nm, and emission was at 530 nm. (A) Miltefosine (4 μM) was added (arrow) directly to the stirring cuvette with promastigotes loaded with acridine orange, followed by the addition of nigericin (2 μM). This was performed in the absence of extracellular Ca²⁺. (B) In the absence of extracellular Ca²⁺, nigericin was added at 2 μM (arrow), followed by miltefosine (4 μM). Traces are representative of at least three independent experiments.

by action of the drug. The consecutive addition of nigericin (2 μM), a known K^+/H^+ exchanger and therefore an inducer of the alkalinization of these organelles, produced a further increase in fluorescence. This might mean that miltefosine was not able to completely alkalinize the acidocalcisomes, or alternatively it would imply the existence in the parasite of other acidic compartments affected by this drug. In Fig. 5B we performed the same experiment but inverted the order of addition of the effectors. It can be noticed that nigericin induced alkalinization of the acidocalcisomes. Addition of miltefosine after nigericin induced a further effect, which could be attributed to the action of this compound on different acidic organelles in which acridine orange accumulates.

DISCUSSION

Miltefosine is the first oral drug prescribed against leishmaniasis and its effects against *L. donovani* are well known, the Old World visceral-leishmaniasis-causing agent. Nevertheless, until the last decade little was known about the mechanism of action of this drug. One of its most remarkable effects is the inhibition of phosphatidylcholine synthesis, being 10 to 20 times more selective for the phosphatidylethanolamine N-methyl-transferase from the parasite compared to its human counterpart, thus explaining its large selectivity against trypanosomatids (15). Other relevant well-described effects of miltefosine are associated with its action on the cytochrome *c* oxidase, explaining the disruption of overall mitochondrial function (19). In this work we report new mechanisms of action for miltefosine. First, we demonstrated that this compound activates a plasma membrane Ca^{2+} channel in *L. donovani*, similar to the human L-type VGCC homolog previously described in *L. mexicana*. Thus, similar to its human counterpart, the channel is activated by the specific L-type VGCC agonist Bay K 8644 and is blocked by dihydropyridines (like nifedipine), which are classical L-type VGCC antagonists. Also similar to the Ca^{2+} channel from *L. mexicana*, this channel is opened by the sphingolipid sphingosine, which is a distinctive feature of the trypano-somatid channel (29). In this context, disruption of intracellular Ca^{2+} homeostasis has been recognized as a putative target for drug action on trypanosomatids (35). The action of many other drugs used against these parasites, such as pentamidine (36), amiodarone (10, 21, 22, 22), dronedarone (23, 24, 37), and SQ109 (25, 26) is mainly through disruption of Ca^{2+} regulation. Accordingly, a large Ca^{2+} entrance to the cell induced by miltefosine should produce a massive impairment of Ca^{2+} function, causing the death of the parasite.

We also demonstrated in this work that miltefosine produced a dramatic, fast, and direct effect on the acidocalcisomes of *L. donovani*. This would also cause an increase in cytoplasmic Ca^{2+}, since alkalinization of these organelles would lead to the release of this cation, thus adding its effect to the action produced by Ca^{2+} entrance through the plasma membrane Ca^{2+} channel. Besides, acidocalcisome impairment would have consequences on the bioenergetics of the parasite, since this organelle is involved in the production and accumulation of pyrophosphates (38), which are considered an alternative energetic coin in trypanosomatids. In turn, this effect should reinforce the well-recognized action of miltefosine on the mitochondrion, since, as mentioned, this drug inhibits the cytochrome *c* oxidase, which produces impairment of the membrane electrochemical membrane potential, the driving force for Ca^{2+} accumulation inside this organelle (32). Related to this point, we cannot discard a possible direct effect of miltefosine on the mitochondrial function, beyond its action on the cytochrome *c* oxidase. Thus, the experiments performed in this work showing the total collapse of the mitochondrial electrochemical membrane potential in seconds, very different from the previously reported long-lasting effect of miltefosine on the membrane potential observed after several hours (19), would support a third effect of this compound in these parasites. This is reinforced by the fact that the results obtained when the experiments were performed in the absence of extracellular Ca^{2+} were very similar, thus discarding an effect that could be attributed to Ca^{2+} entry to the cell through the just-opened plasma membrane Ca^{2+} channel, which would induce the entry of the

Domain III

```
H.sapiens   : FDNVLAAMMALFTVSTFEGWPELLYRSIDSHTEDKGPIYNYRVEISIFFIIYIIIIAFFMMNIFVGFVIVT
L.donovani  : FRNFYESLLTTFEISTGAEWIDVIYSAVDSRSALLSPLRNQRPYLGLVFIAYYYVSHFIFFTLFISAVIYC
L.mexicana  : FRNFYESLLTTFEISTGAEWIDVIYSAVDSRSALLSPLQNQRPYLGLVFIAYYYVSHFIFFTLFISAVIYC
```

Domain IV

```
H.sapiens   : FQTFPQAVLLLFRCATGEAWQDIMLACMP-GKKCAPESEPSNSTEGETPCGS-SFAVFYFISFYMLCAFLIINLF
L.donovani  : FGTFVNALIMVFRLSTLQNWATMLRGSLDRGYYCARAS--------KRCGPTDWAPVYYIPIVICFFLLLSTLY
L.mexicana  : FGTFVNALIMVFRLSTLQNWATMLRGSLDRGYYCTRAS--------KRCGPTDWAPVYYIPIVICFFLLLSTMY
```

FIG 6 Sequence alignments of the IIIS6 and IVS6 domains of human L-Type VGCC (NCBI accession number NP_955630.3) with *L. mexicana* (NCBI accession number XP_003878633.1, gene ID according to TriTrypDB LmxM.33.0480) and *L. donovani* (NCBI accession number CBZ37533.1, gene ID according to TriTrypDB LdBPK_340500.1) homologs. The amino acid sequences next to the selectivity filter are highlighted in gray and the amino acids associated with dihydropyridines (nifedipine) responsiveness are highlighted in gray and underlined (29).

cation to the mitochondria, causing the collapse of its membrane potential. Although these experiments are not conclusive, this possibility remains open. The results suggest that the effect discussed on the mitochondrial membrane potential induced by miltefosine would reinforce its global effect on the increase in the intracellular Ca^{2+} concentration, with the expected overall consequences on the parasite biology. This large increase in the intracellular concentration of this cation could be also the basis for the apoptotic effects on these parasites attributed to miltefosine (20), since it have been demonstrated that an increase in cytoplasmic Ca^{2+} concentration is a condition for cells to take the decision to start the apoptotic fate (39).

In concerns to the presence of a sphingosine-activated homolog of the human L-type VGCC in *L. donovani*, Fig. 6 depicts the sequence alignment of the $\alpha 1C$ subunit of the human channel with *L. mexicana* and *L. donovani* homologs on the relevant domains, including the binding sites for the specific channel blocker nifedipine. This sequence alignment shows that, although there is a 26% homology between the human and the *L. donovani* sequences, there is a 100% homology sequences of the two *Leishmania* species. Furthermore, the complete sequence of the gene for the *L. mexicana* channel is about 94% similar to the *L. donovani* sequence (40). This high homology between this two species explains the similarities observed during this work concerning the opening of the channel by sphingosine, as well as the Bay K 8644 activation and nifedipine antagonism of this parasite channel.

In conclusion, the results shown demonstrate a double effect of miltefosine on *L. donovani*, namely, the opening of the sphingosine-activated plasma membrane Ca^{2+} channel and a direct effect on the acidocalcisomes, which in combination should produce a large intracellular Ca^{2+} accumulation. Interestingly, both mechanisms of actions are parasite-specific. Both effects are correlated with the abrupt increase in the intracellular Ca^{2+} concentration observed in *L. donovani* upon addition of miltefosine. Since the disruption of the parasite Ca^{2+} homeostasis has been claimed as a target for the action of several drugs against trypanosomatids, the results presented here, added to the well-recognized action of miltefosine on phospholipid synthesis and on cytochrome *c* oxidase inhibition, would contribute to the dramatic parasite death induced by this drug and could explain the large benefits attributed to miltefosine.

MATERIALS AND METHODS

Chemicals. Miltefosine (hexadecyl phosphocholine), sphingosine, Bay K 8644, verapamil, EGTA, digitonin, fluorocarbonyl cyanide-*p*-(trifluoromethoxy)phenylhydrazone (FCCP), and nigericin were from Sigma (St. Louis, MO). Fura-2-acetoxymethyl ester (Fura-2-AM), acridine orange, and rhodamine 123 were from Molecular Probes (Eugene, OR).

Culture of *L. donovani* promastigotes. *L. donovani* (DD8 strain) promastigotes were cultured in liver infusion tryptose (LIT) medium supplemented with 10% of fetal bovine serum at 26°C as reported previously (7).

Intracellular Ca^{2+} measurements. *L. donovani* promastigotes were loaded with the Ca^{2+} radiometric indicator Fura-2 as reported previously (24). The fluorophore Fura-2 is excited by two different wavelengths, 340 nm when it is Ca^{2+}-bound and 380 nm when it is free of Ca^{2+}, and emission is recorded at a unique wavelength of 510 nm. Briefly, 1×10^7 parasites were collected by centrifugation at $600 \times g$ for

2 min and washed twice in a loading buffer (137 mM NaCl, 4 mM KCl, 1.5 mM KH_2PO_4, 8.5 mM Na_2HPO_4, 11 mM glucose, 1.8 mM $CaCl_2$, 0.8 mM $MgSO_4$, 20 mM HEPES-NaOH [pH 7.4]). The pellet was resuspended in 1 μM Fura-2-AM (the acetoxymethyl ester derivative of Fura-2), and probenecid (2.4 mM) and pluronic acid (0.05%) were added to the loading buffer. The parasites were incubated at 29°C in the dark with continuous agitation for 2 h. Fura-2-AM-loaded parasites were washed twice in the same buffer, in either the presence or absence of Ca^{2+}. The $CaCl_2$ concentration used in all the experiments where the cation was present was done in the presence of 2 mM Ca^{2+}, mimicking the extracellular concentration present in the growth medium. Additionally, EGTA (500 μM) was added when measurements were made in the absence of extracellular Ca^{2+}. This concentration of EGTA is high enough to chelate all possible contaminant Ca^{2+} and to lower its concentration to a level which favorably competes with the fluorescent Ca^{2+} indicator, making it possible to obtain the minimal fluorescence value. Digitonin (40 μM) is known to permeabilize the parasite cell membrane, allowing Ca^{2+} entrance from the extracellular medium (22). 10 mM EGTA was added at the end of the experiments in order to obtain the maximal and minimal fluorescence values, respectively (29). Fluorescence measurements were carried out on a stirred cuvette at 29°C, using a Perkin-Elmer LS-55 fluorescence spectrometer with a double wavelength excitation beam (340 nm and 380 nm), recording the emission at 510 nm.

Determination of the mitochondrial membrane potential. The effect of miltefosine on the mitochondrial membrane potential of *L. donovani* promastigotes was evaluated using the fluorescent dye rhodamine 123 as reported previously (21), taking advantage of the internalization of the fluorophore, according to the mitochondrial electrochemical membrane potential ($\Delta\varphi$). Briefly, 8×10^6 parasites were collected by centrifugation at $600 \times g$ for 2.5 min and washed in phosphate-buffered saline (PBS) plus 1% glucose. The pellet was resuspended in the same buffer in the presence of rhodamine 123 (20 μM) and incubated for 45 min at 29°C in the dark with continuous stirring. Subsequently, parasites were washed twice and resuspended in the same buffer, and then transferred to a stirred cuvette. Measurements (excitation wavelength [λ_{ext}], 488 nm; emission wavelength [λ_{em}], 530 nm) were made in a Hitachi 7000 spectrofluorimeter at 29°C. The protonophore FCCP (2 μM) was used as a positive control.

Determination of acidocalcisome alkalinization. The effect of miltefosine on acidocalcisomes was evaluated using acridine orange, which is accumulated in acidic compartments (22). Promastigotes (8×10^6 cells/ml) were collected, washed, and incubated in a loading buffer (the same used in mitochondrial membrane potential measurements) with acridine orange at 2 μM for 5 min at 29°C in the dark and with constant stirring. Measurements were performed with λ_{ext} at 488 nm and λ_{em} at 530 nm at 29°C in a Hitachi 7000 spectrofluorimeter under magnetic stirring. Nigericin, a K^+/H^+ exchanger that is known to alkalinize the acidocalcisomes, was used at 2 μM as a positive control. This concentration of nigericin exceeds the amount required for complete release of acridine orange from acidocalcisomes (41).

REFERENCES

1. Ready PD. 2014. Epidemiology of visceral leishmaniasis. Clin Epidemiol 6:147–154. https://doi.org/10.2147/CLEP.S44267.
2. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. 2012. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist 2:11–19. https://doi.org/10.1016/j.ijpddr.2012.01.003.
3. Croft SL, Neal RA, Pendergast W, Chan JH. 1987. The activity of alkyl phosphorylcholines and related derivatives against *Leishmania don-ovani*. Biochem Pharmacol 36:2633–2636. https://doi.org/10.1016/0006-2952(87)90543-0.
4. Eibl H, Unger C. 1990. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat Rev 17:233–242. https://doi.org/10.1016/0305-7372(90)90053-l.
5. Croft SL, Snowdon D, Yardley V. 1996. The activities of four anticancer alkyllysophospholipids against *Leishmania donovani*, *Trypanosoma cruzi* and *Trypanosoma brucei*. J Antimicrob Chemother 38:1041–1047. https://doi.org/10.1093/jac/38.6.1041.
6. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J. 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341:1795–1800. https://doi.org/10.1056/NEJM199912093412403.
7. Morais-Teixeira E de, Damasceno QS, Galuppo MK, Romanha AJ, Rabello A. 2011. The *in vitro* leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant *Leishmania* species of Brazil. Mem Inst Oswaldo Cruz 106:475–478. https://doi.org/10.1590/S0074-02762011000400015.
8. Escobar P, Matu S, Marques C, Croft SL. 2002. Sensitivities of *Leishmania* species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfos-ine) and amphotericin B. Acta Trop 81:151–157. https://doi.org/10.1016/S0001-706X(01)00197-8.
9. Tiwari B, Pahuja R, Kumar P, Rath SK, Gupta KC, Goyal N. 2017. Nanotized curcumin and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis. Antimicrob Agents Chemother 61:e01169-16. https://doi.org/10.1128/AAC.01169-16.
10. Serrano-Martín X, Payares G, De Lucca M, Martinez JC, Mendoza-León A, Benaim G. 2009. Amiodarone and miltefosine act synergistically against *Leishmania mexicana* and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 53:5108–5113. https://doi.org/10.1128/AAC.00505-09.
11. Farca AM, Miniscalco B, Badino P, Odore R, Monticelli P, Trisciuoglio A, Ferroglio E. 2012. Canine leishmaniosis: *in vitro* efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against

clinical strains of *Leishmania infantum*. Parasitol Res 110:2509–2513. https://doi.org/10.1007/s00436-011-2792-7.

12. Faucher J-F, Morquin D, Reynes J, Chirouze C, Hoen B, Le Moing V. 2016. Serial use of pentamidine and miltefosine for treating *Leishmania infantum*-HIV coinfection. Parasitol Int 65:444–446. https://doi.org/10.1016/j.parint.2016.06.009.

13. Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW. 1999. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 93:589–597.

14. Agrawal VK, Singh Z. 2006. Miltefosine: First oral drug for treatment of visceral leishmaniasis. Med J Armed Forces India 62:66–67. https://doi.org/10.1016/S0377-1237(06)80162-0.

15. Urbina JA. 2006. Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites. Trans R Soc Trop Med Hyg 100(Suppl 1):S9–S16. https://doi.org/10.1016/j.trstmh.2006.03.010.

16. Lira R, Contreras LM, Rita RMS, Urbina JA. 2001. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite *Trypanosoma cruzi*: potentiation of *in vitro* activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 47:537–546. https://doi.org/10.1093/jac/47.5.537.

17. Wieder T, Orfanos CE, Geilen CC. 1998. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J Biol Chem 273:11025–11031. https://doi.org/10.1074/jbc.273.18.11025.

18. Rakotomanga M, Blanc S, Gaudin K, Chaminade P, Loiseau PM. 2007. Miltefosine affects lipid metabolism in *Leishmania donovani* promastigotes. Antimicrob Agents Chemother 51:1425–1430. https://doi.org/10.1128/AAC.01123-06.

19. Luque-Ortega JR, Rivas L. 2007. Miltefosine (hexadecylphosphocholine) inhibits cytochrome *c* oxidase in *Leishmania donovani* promastigotes. Antimicrob Agents Chemother 51:1327–1332. https://doi.org/10.1128/AAC.01415-06.

20. Paris C, Loiseau PM, Bories C, Bréard J. 2004. Miltefosine induces apoptosis-like death in *Leishmania donovani* promastigotes. Antimicrob Agents Chemother 48:852–859. https://doi.org/10.1128/AAC.48.3.852-859.2004.

21. Benaim G, Sanders JM, Garcia-Marchán Y, Colina C, Lira R, Caldera AR, Payares G, Sanoja C, Burgos JM, Leon-Rossell A, Concepcion JL, Schijman AG, Levin M, Oldfield E, Urbina JA. 2006. Amiodarone has intrinsic anti-*Trypanosoma cruzi* activity and acts synergistically with posaconazole. J Med Chem 49:892–899. https://doi.org/10.1021/jm050691f.

22. Serrano-Martín X, García-Marchan Y, Fernandez A, Rodriguez N, Rojas H, Visbal G, Benaim G. 2009. Amiodarone destabilizes intracellular Ca^{2+} homeostasis and biosynthesis of sterols in *Leishmania mexicana*. Antimicrob Agents Chemother 53:1403–1410. https://doi.org/10.1128/AAC.01215-08.

23. Benaim G, Hernandez-Rodriguez V, Mujica-Gonzalez S, Plaza-Rojas L, Silva ML, Parra-Gimenez N, Garcia-Marchan Y, Paniz-Mondolfi A, Uzcanga G. 2012. *In vitro* anti-*Trypanosoma cruzi* activity of dronedarone, a novel amiodarone derivative with an improved safety profile. Antimicrob Agents Chemother 56:3720–3725. https://doi.org/10.1128/AAC.00207-12.

24. Benaim G, Casanova P, Hernandez-Rodriguez V, Mujica-Gonzalez S, Parra-Gimenez N, Plaza-Rojas L, Concepcion JL, Liu Y-L, Oldfield E, Paniz-Mondolfi A, Suarez AI. 2014. Dronedarone, an amiodarone analog with improved anti-*Leishmania mexicana* efficacy. Antimicrob Agents Chemother 58:2295–2303. https://doi.org/10.1128/AAC.01240-13.

25. Veiga-Santos P, Li K, Lameira L, Carvalho TMU de, Huang G, Galizzi M, Shang N, Li Q, Gonzalez-Pacanowska D, Hernandez-Rodriguez V, Benaim G, Guo R-T, Urbina JA, Docampo R, Souza W de, Oldfield E. 2015. SQ109,

26. García-García V, Oldfield E, Benaim G. 2016. Inhibition of *Leishmania mexicana* growth by the tuberculosis drug SQ109. Antimicrob Agents Chemother 60:6386–6389. https://doi.org/10.1128/AAC.00945-16.

27. De Rycker M, Thomas J, Riley J, Brough SJ, Miles TJ, Gray DW. 2016. Identification of trypanocidal activity for known clinical compounds using a new *Trypanosoma cruzi* hit-discovery screening cascade. PLoS Negl Trop Dis 10:e0004584. https://doi.org/10.1371/journal.pntd.0004584.

28. Kashif M, Manna PP, Akhter Y, Alaidarous M, Rub A. 2017. Screening of novel inhibitors against *Leishmania donovani* calcium ion channel to fight leishmaniasis. Infect Disord Drug Targets 17:120–129. https://doi.org/10.2174/1871526516666161230124513.

29. Benaim G, García-Marchán Y, Reyes C, Uzcanga G, Figarella K. 2013. Identification of a sphingosine-sensitive Ca^{2+} channel in the plasma membrane of *Leishmania mexicana*. Biochem Biophys Res Commun 430:1091–1096. https://doi.org/10.1016/j.bbrc.2012.12.033.

30. Verma NK, Dey CS. 2004. possible mechanism of miltefosine-mediated death of *Leishmania donovani*. Antimicrob Agents Chemother 48:3010–3015. https://doi.org/10.1128/AAC.48.8.3010-3015.2004.

31. De Stefani D, Raffaello A, Teardo E, Szabò I, Rizzuto R. 2011. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 476:336–340. https://doi.org/10.1038/nature10230.

32. Benaim G, Bermudez R, Urbina JA. 1990. Ca2+ transport in isolated mitochondrial vesicles from *Leishmania braziliensis* promastigotes. Mol Biochem Parasitol 39:61–68. https://doi.org/10.1016/0166-6851(90)90008-A.

33. Vercesi AE, Bernardes CF, Hoffmann ME, Gadelha FR, Docampo R. 1991. Digitonin permeabilization does not affect mitochondrial function and allows the determination of the mitochondrial membrane potential of *Trypanosoma cruzi in situ*. J Biol Chem 266:14431–14434.

34. Vercesi AE, Rodrigues CO, Catisti R, Docampo R. 2000. Presence of a Na^+/H^+ exchanger in acidocalcisomes of *Leishmania donovani* and their alkalization by anti-leishmanial drugs. FEBS Lett 473:203–206. https://doi.org/10.1016/S0014-5793(00)01531-3.

35. Benaim G, Garcia CR. 2011. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis—a review. Trop Biomed 28:471–481.

36. Benaim G, Lopez-Estraño C, Docampo R, Moreno SN. 1993. A calmodulin-stimulated Ca^{2+} pump in plasma-membrane vesicles from *Trypanosoma brucei*; selective inhibition by pentamidine. Biochem J 296(Part 3):759–763.

37. Benaim G, Paniz Mondolfi AE. 2012. The emerging role of amiodarone and dronedarone in Chagas disease. Nat Rev Cardiol 9:605–609. https://doi.org/10.1038/nrcardio.2012.108.

38. Docampo R, de Souza W, Miranda K, Rohloff P, Moreno SNJ. 2005. Acidocalcisomes—conserved from bacteria to man. Nat Rev Microbiol 3:251–261. https://doi.org/10.1038/nrmicro1097.

39. Pimentel AA, Benaim G. 2012. [Ca2+ and sphingolipids as modulators for apoptosis and cancer]. Invest Clin 53:84–110. (In Spanish.)

40. Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, de Doncker S, Maes I, Mottram JC, Quail MA, Rijal S, Sanders M, Schönian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin J-C, Berriman M. 2011. Whole genome sequencing of multiple *Leishmania donovani* clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res 21:2143–2156. https://doi.org/10.1101/gr.123430.111.

41. Docampo R, Scott DA, Vercesi AE, Moreno SN. 1995. Intracellular Ca^{2+} storage in acidocalcisomes of *Trypanosoma cruzi*. Biochem J 310(Part 3):1005–1012. https://doi.org/10.1042/bj3101005.